US FDA User Fees
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
EU Fees Revision A ‘Once-In-A-Generation’ Chance To Solve Resource Challenges
COVID-19 and Brexit have put a great strain on the resources of the EU medicines regulatory system, but the planned review of the EU fee system could produce a system that is more flexible, efficient and better able to respond rapidly to emerging technologies and the needs of health care systems, says EFPIA.
UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”
FDA Reforms Missed By FDORA Could Find Vehicle In Animal Drug User Fee, Pandemic Bills
The usually lower-profile user fee reauthorizations could gain more attention for broader US FDA issues, said Andi Lipstein Fristedt, FDA deputy commissioner for policy, legislation and international affairs.
Generic Application Mystery: Few ANDAs Withdrawn To Start FY 2023
In past years, sponsors have pulled ANDAs at the beginning of a fiscal year in part to control their GDUFA program fee payments, but no approved ANDAs were withdrawn during the first two months of FY 2023.
Swedish EU Presidency Promises Action On Pharma Law Revision, EMA Fees & AMR
Health care and medicines are among the priorities outlined by the new presidency of the Council of the EU for the first half of 2023.
US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies
US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
New EU Fee System To Give Pharma Firms More Predictability
The publication of a draft EU Regulation governing the fees paid by the pharmaceutical industry to the European Medicines Agency is the latest step in a long process aimed at ensuring that the payment system better reflects the actual costs of the regulatory work carried out or coordinated by the EU regulator.
US FDA Shutdown Plan Decreases Potential Furloughs Again, Thanks To User Fee Carryover Funds
More than 80% of FDA employees would continue working during a government shutdown, which appears unlikely as congressional negotiators announce a ‘framework’ agreement.
US FDA Collects ‘Majority’ Of PDUFA Program Fees After Payment Plea
The revenue is expected to sustain the prescription drug user fee program moving forward after reserves were tapped at the start of fiscal year 2023.
US FDA’s New Acting Generics Chief Relearning System After 24 Years Of Experience
Acting OGD Director Susan Rosencrance says in an interview that the generics assessment system has evolved substantially since she moved to the Office of Pharmaceutical Quality in 2015.
RWE Program Offers Sponsors Chance At Novel Uses, But In Exchange For Disclosing Proposals
The disclosure requirement to participate includes an option for the US FDA to include the ideas on new regulatory uses for real-world evidence in a guidance or speak about them at public forums in order to ‘promote innovation.’
US FDA User Fee Staffing: The Objective Capacity Planning Adjuster Often Needs Subjective Review
The FDA has overruled the results from its own formula intended to match resource levels with workload every time except once.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.